Rademikibart  (Synonyms: CBP-201)

Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a K_D of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Rademikibart binds specifically to human IL-4Rα with high affinity, exhibiting an equilibrium dissociation constant of 20.7 pM, and does not cross-react with non-human mammalian IL-4Rα^[1].
Rademikibart effectively inhibits STAT6 signaling in HEK cells^[1].
Rademikibart effectively inhibits Th2-stimulated cytokine expression in human skin explants^[1].
Rademikibart potently inhibits IL-4- and IL-13-induced TARC release from human peripheral blood mononuclear cells, with IC₅₀ values of 59.1 ng/mL and 13.6 ng/mL, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3566  [NCBI]

P24394

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.36 kDa

2648260-80-2

Liquid

Colorless to light yellow

[Rademikibart]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized IL-4R alpha/CD124 Protein, Human can bind Rademikibart. The EC₅₀ for this effect is 4.99 ng/mL.
• 
  Flow cytometric analysis of 1.5×10⁶ Ramos cells with Rademikibart (HY-P990090, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Wang J, et al. Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci. 2023 Dec;16(12):2614-2627.

  [2]. Collazo, et al. Rapid Improvement in Lung Function Observed With Rademikibart in Patients With Moderate-to-Severe Uncontrolled Asthma. AJRCCM. 2025 May 01;211(Supplement_1):A5041.
  

  [3]. Collazo, et al. Effect of Rademikibart on Blood Eosinophil Counts in Patients With
  Asthma: Is There an IL-4Rα Class Effect? AJRCCM. 2025 May 01;211(Supplement_1):A1339.